In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

@article{Pfaller2004InVA,
  title={In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.},
  author={Michael A. Pfaller and Shawn A. Messer and Linda D Boyken and Richard J. Hollis and Cassie L Rice and Shailesh Tendolkar and Daniel J. Diekema},
  journal={Diagnostic microbiology and infectious disease},
  year={2004},
  volume={48 3},
  pages={
          201-5
        }
}
We examined the in vitro activities of voriconazole, posaconazole, and fluconazole against 3,932 isolates of Candida spp. and 237 isolates of Cryptococcus neoformans obtained from over 100 medical centers worldwide during 2001 and 2002. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards (NCCLS) methods using RPMI 1640 as the test medium. Voriconazole and posaconazole were very active… Expand
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
TLDR
Voriconazole MICs correlate with those of fluconazole and itraconazoles and may predict clinical outcome, and patients with voriconzole-resistant isolates showed a 56% response to vorIconazole therapy, and those patients with susceptible isolates showing a 71% response. Expand
In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China
This study analyzed the in vitro drug sensitivity of Cryptococcus spp. from Guangxi, Southern China. One hundred three strains of Cryptococcus were recovered from 86 patients; 14 were HIV positiveExpand
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
TLDR
The in vitro activity of caspofungin against 8,197 invasive patient isolates of Candida collected from 91 medical centers worldwide from 1 January 2001 to 31 December 2004 was determined and prospective sentinel surveillance reveals no evidence of emerging casp ofungin resistance among invasive clinical isolatesof Candida. Expand
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
TLDR
Voriconazole shows activity, in vitro, similar to that of itraconazole against a wide range of moulds and is also active against some isolates not susceptible to itraconsazole or amphotericin B, but not the Zygomycetes. Expand
Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002
TLDR
All 46 isolates that were resistant to fluconazole were susceptible to caspofungin and flucytosine and exhibited variable cross-resistance to posaconazole, ravuconazoles, and voriconazole. Expand
Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Cryptococcus diffluens is a recently re-established species that shares several phenotypic features with Cryptococcus neoformans. We evaluated the application of the Clinical Laboratory StandardsExpand
Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
TLDR
The TREK dried microdilution panel appears to be a viable alternative to frozen-broth microdILution panels for testing of Candida spp. Expand
The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
TLDR
Resistance is uncommon in C. albicans isolates recovered from blood cultures, while biofilm production is a relatively frequent event, and periodic surveillance is warranted to monitor the incidence of in vitro antifungal resistance as well as of biofilmProduction. Expand
Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish tertiary care military hospital, recovered through 2001 and 2006.
TLDR
increasing prevalence of C. parapsilosis emphasizes a need for better catheter care and continuous surveillance programs, and antifungal susceptibility of Candida bloodstream isolates is evaluated retrospectively. Expand
Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait
TLDR
The antifungal resistance among bloodstream isolates of C. parapsilosis against AP, FL, FC and VO in Kuwait is rare, and this is the first report on CS susceptibility of caspofungin isolates from Arabian Gulf region. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans
TLDR
Posaconazoles was more active than itraconazole and fluconazole against all Candida spp. Expand
In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp
TLDR
R ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazoles against all Candida spp. Expand
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
TLDR
In vitro activity of voriconazole compared to those of fluconazole and itraconazole against 566 clinical isolates of Cryptococcus neoformans from Africa and the United States suggest that it may be useful in the treatment of cryptococcosis. Expand
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
TLDR
Voriconazole showed excellent in vitro activity against most of the 50 species of dematiaceous fungi tested, but the activity of all the agents was poor against most isolates of Scedosporium prolificans and Phaeoacremonium parasiticum (Phialophora parasitica). Expand
In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood
TLDR
In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Expand
In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens
TLDR
In vitro data suggest that the new antifungal triazole SCH has significant potential for clinical development and is considerably more active than FLC and slightly moreactive than either ITC and KETO. Expand
International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program
TLDR
Observations suggest susceptibility patterns and trends among yeast isolates from BSI and raise additional questions that can be answered only by continued surveillance and clinical investigations of the type reported here (SENTRY Program). Expand
Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts
TLDR
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined. Expand
Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000
TLDR
Differences in the species distributions of pathogens and differences in antifungal resistance among isolates from individuals in the pediatric and adult age groups are demonstrated. Expand
...
1
2
...